Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,deferredLongTermLiab,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,longTermDebt,inventory,accountsPayable,deferredLongTermAssetCharges,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,repurchaseOfStock,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,currency,priceHint,exchange,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchangeDataDelayedBy,shortName,marketState,market,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,trailingPE,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,forwardPE,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jun 29, 2021) 4","Short Ratio (Jun 29, 2021) 4","Short % of Float (Jun 29, 2021) 4","Short % of Shares Outstanding (Jun 29, 2021) 4","Shares Short (prior month May 27, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry,address2
t0,EBS,608100000.0,53585500,,,85200000,,69700000,80900000,191200000,95400000,95400000,,-8500000,,,,15500000,343000000,247600000,151800000,-10200000,,69700000,69700000,648200000.0,790100000.0,1377300000.0,1522800000.0,3100000.0,111000000.0,2900100000.0,100000.0,2200000.0,796600000.0,140800000.0,266500000.0,-64000000.0,81700000.0,547800000.0,370200000.0,31700000.0,-24400000.0,722600000.0,1181100000.0,184400000.0,840000000.0,406500000.0,142200000.0,,29500000,-56100000,-16200000,-22200000,-79400000,6900000,-73500000,-12200000,-300000,5100000,28700000,-99900000,42100000,-700000,13400000,-56100000,810900000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,2,NYQ,62.77,1630507094,-0.31000137,63.14,63.2,62.49,30347,0,"Emergent Biosolutions, Inc.",REGULAR,us_market,-0.4914416,62.49 - 63.2,63.08,62.65,62.79,8,14,finmb_13627017,NYSE,Emergent BioSolutions Inc.,USD,564695,345150,7.700001,0.13982207,55.07 - 127.2,-64.42999,-0.5065251,55.07,127.2,1619726400,1635969600,1636401600,8.820967,0.0041682543,71.490944,-8.720943,-0.12198669,12.283757,7.116,5.11,7.92,7.925505,28.41,62.509445,0.26055527,3363561984,2.2094333,15,America/New_York,EDT,-14400000,False,False,0.98,,,127.2,55.07,62.51,71.49,564.7k,345.15k,53.59M,,47.91M,9.46%,85.83%,3.58M,4.27,8.29%,6.68%,2.74M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",22.70%,35.26%,14.52%,29.82%,1.71B,32.17,78.20%,857.6M,711.8M,387.3M,7.12,,547.8M,10.22,903.3M,59.32,3.19,28.41,483.3M,315.64M,Value,20879,Healthcare,2200,2,7,"Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response products and solutions for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers ACAM2000, a smallpox vaccine; BioThrax, an anthrax vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. The company also provides NARCAN for the emergency treatment of known or suspected opioid overdose; and Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin. In addition, it offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; and Trobigard a combination drug-device auto injector product candidate. Further, the company is developing COVID-EIG and COVID-HIG potential treatments to COVID-19 disease; and FLU-IGIV for the treatment of Influenza A infection in hospitalized patients. Additionally, it provides contract development and manufacturing service that comprises development services, drug substance manufacturing, and drug product manufacturing in the pharmaceutical and biotechnology industries, as well as the governments and non-governmental organizations. The company has collaboration agreements with Novavax Inc.; and Johnson & Johnson. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.",Gaithersburg,240 631 3200,MD,7,1609372800,1625097600,7,United States,http://www.emergentbiosolutions.com,86400,6,400 Professional Drive,240 631 3203,Drug Manufacturersâ€”Specialty & Generic,Suite 400
t-1,EBS,517200000.0,53585500,,,252800000,,185400000,82100000,355600000,258500000,258500000,,-8700000,,,,67400000,583000000,324500000,227400000,-5700000,,185400000,185400000,663100000.0,784900000.0,1436200000.0,1447000000.0,,72000000.0,2883200000.0,100000.0,2200000.0,726900000.0,173600000.0,266700000.0,-64900000.0,82400000.0,621300000.0,384500000.0,39500000.0,-25300000.0,675100000.0,1195900000.0,230900000.0,850300000.0,307000000.0,136100000.0,,29400000,-36000000,-5700000,-2300000,54900000,5000000,206300000,-1000000,-500000,245100000,28900000,-35600000,-25600000,-600000,6600000,-26000000,811400000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,2,NYQ,62.77,1630507094,-0.31000137,63.14,63.2,62.49,30347,0,"Emergent Biosolutions, Inc.",REGULAR,us_market,-0.4914416,62.49 - 63.2,63.08,62.65,62.79,8,14,finmb_13627017,NYSE,Emergent BioSolutions Inc.,USD,564695,345150,7.700001,0.13982207,55.07 - 127.2,-64.42999,-0.5065251,55.07,127.2,1619726400,1635969600,1636401600,8.820967,0.0041682543,71.490944,-8.720943,-0.12198669,12.283757,7.116,5.11,7.92,7.925505,28.41,62.509445,0.26055527,3363561984,2.2094333,15,America/New_York,EDT,-14400000,False,False,0.98,,,127.2,55.07,62.51,71.49,564.7k,345.15k,53.59M,,47.91M,9.46%,85.83%,3.58M,4.27,8.29%,6.68%,2.74M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",22.70%,35.26%,14.52%,29.82%,1.71B,32.17,78.20%,857.6M,711.8M,387.3M,7.12,,547.8M,10.22,903.3M,59.32,3.19,28.41,483.3M,315.64M,Value,20879,Healthcare,2200,2,7,"Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response products and solutions for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers ACAM2000, a smallpox vaccine; BioThrax, an anthrax vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. The company also provides NARCAN for the emergency treatment of known or suspected opioid overdose; and Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin. In addition, it offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; and Trobigard a combination drug-device auto injector product candidate. Further, the company is developing COVID-EIG and COVID-HIG potential treatments to COVID-19 disease; and FLU-IGIV for the treatment of Influenza A infection in hospitalized patients. Additionally, it provides contract development and manufacturing service that comprises development services, drug substance manufacturing, and drug product manufacturing in the pharmaceutical and biotechnology industries, as well as the governments and non-governmental organizations. The company has collaboration agreements with Novavax Inc.; and Johnson & Johnson. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.",Gaithersburg,240 631 3200,MD,7,1609372800,1625097600,7,United States,http://www.emergentbiosolutions.com,86400,6,400 Professional Drive,240 631 3203,Drug Manufacturersâ€”Specialty & Generic,Suite 400
t-2,EBS,306900000.0,53585500,,,55000000,,39500000,75500000,180800000,90300000,90300000,,-7600000,,,,15500000,385200000,294900000,204400000,-35300000,,39500000,39500000,678100000.0,770900000.0,1364800000.0,1251500000.0,40800000.0,43800000.0,2616300000.0,100000.0,200000.0,541500000.0,185600000.0,266500000.0,-61000000.0,83000000.0,415000000.0,299300000.0,36500000.0,-21400000.0,629900000.0,958800000.0,196100000.0,859200000.0,270100000.0,102800000.0,,-13000000,-45700000,94200000,87100000,-47600000,3500000,146200000,-1100000,-400000,105200000,28800000,-33900000,62500000,-9500000,68000000,-45700000,659500000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,2,NYQ,62.77,1630507094,-0.31000137,63.14,63.2,62.49,30347,0,"Emergent Biosolutions, Inc.",REGULAR,us_market,-0.4914416,62.49 - 63.2,63.08,62.65,62.79,8,14,finmb_13627017,NYSE,Emergent BioSolutions Inc.,USD,564695,345150,7.700001,0.13982207,55.07 - 127.2,-64.42999,-0.5065251,55.07,127.2,1619726400,1635969600,1636401600,8.820967,0.0041682543,71.490944,-8.720943,-0.12198669,12.283757,7.116,5.11,7.92,7.925505,28.41,62.509445,0.26055527,3363561984,2.2094333,15,America/New_York,EDT,-14400000,False,False,0.98,,,127.2,55.07,62.51,71.49,564.7k,345.15k,53.59M,,47.91M,9.46%,85.83%,3.58M,4.27,8.29%,6.68%,2.74M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",22.70%,35.26%,14.52%,29.82%,1.71B,32.17,78.20%,857.6M,711.8M,387.3M,7.12,,547.8M,10.22,903.3M,59.32,3.19,28.41,483.3M,315.64M,Value,20879,Healthcare,2200,2,7,"Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response products and solutions for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers ACAM2000, a smallpox vaccine; BioThrax, an anthrax vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. The company also provides NARCAN for the emergency treatment of known or suspected opioid overdose; and Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin. In addition, it offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; and Trobigard a combination drug-device auto injector product candidate. Further, the company is developing COVID-EIG and COVID-HIG potential treatments to COVID-19 disease; and FLU-IGIV for the treatment of Influenza A infection in hospitalized patients. Additionally, it provides contract development and manufacturing service that comprises development services, drug substance manufacturing, and drug product manufacturing in the pharmaceutical and biotechnology industries, as well as the governments and non-governmental organizations. The company has collaboration agreements with Novavax Inc.; and Johnson & Johnson. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.",Gaithersburg,240 631 3200,MD,7,1609372800,1625097600,7,United States,http://www.emergentbiosolutions.com,86400,6,400 Professional Drive,240 631 3203,Drug Manufacturersâ€”Specialty & Generic,Suite 400
t-3,EBS,210300000.0,53585500,,,120700000,,92700000,76000000,217000000,126000000,126000000,,-6400000,,,,28000000,394700000,268700000,177700000,-5300000,,92700000,92700000,722200000.0,758500000.0,1267300000.0,1198800000.0,40600000.0,76900000.0,2466100000.0,100000.0,200000.0,502000000.0,182000000.0,266300000.0,-61800000.0,77100000.0,268800000.0,293700000.0,34700000.0,-22200000.0,604600000.0,795900000.0,258600000.0,770000000.0,236200000.0,84800000.0,22300000.0,29700000,-45100000,-2800000,4700000,33800000,14000000,87300000,-6100000,-200000,127900000,28600000,11900000,-96100000,-400000,26500000,-45100000,502200000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,2,NYQ,62.77,1630507094,-0.31000137,63.14,63.2,62.49,30347,0,"Emergent Biosolutions, Inc.",REGULAR,us_market,-0.4914416,62.49 - 63.2,63.08,62.65,62.79,8,14,finmb_13627017,NYSE,Emergent BioSolutions Inc.,USD,564695,345150,7.700001,0.13982207,55.07 - 127.2,-64.42999,-0.5065251,55.07,127.2,1619726400,1635969600,1636401600,8.820967,0.0041682543,71.490944,-8.720943,-0.12198669,12.283757,7.116,5.11,7.92,7.925505,28.41,62.509445,0.26055527,3363561984,2.2094333,15,America/New_York,EDT,-14400000,False,False,0.98,,,127.2,55.07,62.51,71.49,564.7k,345.15k,53.59M,,47.91M,9.46%,85.83%,3.58M,4.27,8.29%,6.68%,2.74M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",22.70%,35.26%,14.52%,29.82%,1.71B,32.17,78.20%,857.6M,711.8M,387.3M,7.12,,547.8M,10.22,903.3M,59.32,3.19,28.41,483.3M,315.64M,Value,20879,Healthcare,2200,2,7,"Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response products and solutions for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers ACAM2000, a smallpox vaccine; BioThrax, an anthrax vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. The company also provides NARCAN for the emergency treatment of known or suspected opioid overdose; and Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin. In addition, it offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; and Trobigard a combination drug-device auto injector product candidate. Further, the company is developing COVID-EIG and COVID-HIG potential treatments to COVID-19 disease; and FLU-IGIV for the treatment of Influenza A infection in hospitalized patients. Additionally, it provides contract development and manufacturing service that comprises development services, drug substance manufacturing, and drug product manufacturing in the pharmaceutical and biotechnology industries, as well as the governments and non-governmental organizations. The company has collaboration agreements with Novavax Inc.; and Johnson & Johnson. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.",Gaithersburg,240 631 3200,MD,7,1609372800,1625097600,7,United States,http://www.emergentbiosolutions.com,86400,6,400 Professional Drive,240 631 3203,Drug Manufacturersâ€”Specialty & Generic,Suite 400
